New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:09 EDTSLXPSalix risk/reward favorable ahead of trial, says Stifel
Stifel is comfortable owning Salix ahead of the expected release of TARGET-3 retreatment data for Xifaxan in diarrhea-related IBS in coming weeks. The firm thinks the stock could rise significantly if the data is positive, while a decline in shares on negative results would create a buying opportunity. The firm thinks there is a 65%-70% chance that the data will be positive, and it estimates that the stock could climb up to 20%-25% on positive data. It keeps a Buy rating on the stock.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
18:18 EDTSLXPGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
October 21, 2014
07:07 EDTSLXPSalix to present results of TARGET 3 study with Rifaximin 550mg for IBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use